Pigs are an important translational research model for biomedical imaging studies, and especially for modeling diseases of the liver. Dynamic contrast enhanced (DCE)-MRI is experimentally used to measure liver function in humans, but has never been characterized in pig liver. Here we performed DCE-MRI of pig liver following the delivery of two FDA approved hepato-specific MRI contrast agents, Gd-EOB-DTPA (Eovist) and Gd-BOPTA (Multihance), and the non-hepatospecific agent Magnevist, and optimized the anesthesia and animal handling protocol to acquire robust data. A single pig underwent 5 scanning sessions over six weeks, each time injected at clinical dosing either with Eovist (twice), Multihance (twice) or Magnevist (once). DCE-MRI was performed at 1.5T for 60 minutes. DCE-MRI showed rapid hepatic MRI signal enhancement following IV injection of Eovist or Multihance. Efflux of contrast agent from liver exhibited kinetics similar to that in humans, except for one hyperthermic animal where efflux was very fast. As expected, Magnevist was non-enhancing in the liver. The hepatic signal enhancement from Eovist matched that seen in humans and primates, while the hepatic signal enhancement from Multihance was different, similar to rodents and dogs, likely the result of differential hepatic organic anion transport polypeptides. This first experience with these agents in pigs provides valuable information on contrast agent dynamics in normal pig liver. Given the disparity in contrast agent uptake kinetics with humans for Multihance, Eovist should be used in porcine models for biomedical imaging. Proper animal health maintenance, especially temperature, seems essential for accurate and reproducible results.
Introduction
Pigs are a valuable translational biomedical tool, particularly for modeling human liver disease. Robust porcine models of cirrhosis [1] [2] [3] [4] , non-alcoholic steatohepatitis 5, 6 , hepatocellular carcinoma 7, 8 , diabetes [9] [10] [11] , hereditary tyrosinemia type 1 [12] [13] [14] [15] and acute liver failure 16, 17 have all been reported and mimic many clinical manifestations of the human disease. Biomedical imaging can be used in conjunction with these porcine models in many ways. For example, because pigs have similar anatomy (size, organization and location of organs) and physiology to humans, new biomedical imaging protocols can be developed in pig models of disease to better diagnose humans with disease, both at an earlier stage of disease and to follow treatment. Further, biomedical imaging can provide imaging biomarkers to support research and development for treatments for these diseases.
There are two FDA-approved MRI contrast agents that exhibit uptake in the human liver, Gd-EOB-DTPA (Eovist) and Gd-BOPTA (Multihance), mediated by organic anion transport polypeptides (OATP) OATP1B1 and OATP1B3 18 . In humans, Eovist exhibits rapid hepatic uptake with ~ 50:50 clearance by the healthy liver and kidney following IV injection 18 
, while
Multihance exhibits low hepatic uptake with ~ 5:95 clearance by the healthy liver and kidney 19 .
Despite the different pharmacokinetics, both hepatospecific MRI contrast agents enable useful clinical MRI examinations, not only discriminating anatomic disease features in the liver, such as tumors, but also enabling the measurement of hepatic functional deficits.
While extensive data on hepatic uptake of these agents exists in humans and rodents (uptake transporters OATP1A1 and OATP1B2) 20, 21 , and to some extent in dogs and rabbits (uptake transporter OATP1B4) [22] [23] [24] , there is no data on the hepatic uptake of these two hepatospecific MRI contrast agents in pigs (uptake transporter OATP1B4). Further, given the high sensitivity of animal physiology for hepatic function, proper animal handling protocols for pigs need to be established 25 . Given the aforementioned importance of pigs for modeling human liver disease and the potential for biomedical imaging in this regard, the narrow goals of this work were to 1) perform dynamic contrast enhanced (DCE)-MRI studies in pigs using these two hepatospecific MRI contrast agents, providing baseline assessments for contrast agent hepatic influx in normal pig liver, and 2) to determine optimal experimental animal protocols for acquiring high quality DCE-MRI data. Equivalent human clinical gadolinium dose was administered each session for each contrast agent, which is different depending on the agent. Experiments were staggered by 1 or 2 weeks to ensure complete elimination of the agent in between sessions and for scheduling considerations. After the fifth TR, rapid injection (delivered in < 2 s) of contrast agent according to Table   1 was performed as a manual IV bolus via ear vein catheter, followed by ~10 mL manual IV bolus saline flush. Following DCE-MRI, an anatomical image of the abdomen was acquired to confirm accumulation of the agent into the bladder. Following all but the last MRI, the pig was recovered, 
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Results
All MRI sessions were successful, in that the pig remained anesthetized and stable during the MRI, high quality data was acquired, and the pig was recovered (except for the last scan where the pig was euthanized as planned). Table 1 ), a very rapid hepatic signal enhancement is seen, with a rapid, linear decrease in signal intensity for the rest of the scan session. The CBT after the scan session was 107.2°F. In the second Multihance trial (Multihance 2, scan session 3 in Table 1 ) the addition of a cooling pad resulted in 98.8°F CBT and MRI results showed peak hepatic signal enhancement of 65% enhancement over baseline at ~11 minutes post injection, with gradual signal decline to 45% enhancement at 60 minutes post injection. Distribution of Multihance in the blood occurred rapidly as with Eovist.
Clinical chemistry blood serum analysis showed that alkaline phosphatase (ALP) was slightly elevated during the entire experimental period, compared to normal values. Creatine kinase (CK) was highly elevated at scan session 2, 3 and 4 versus 1 and 5 but without control values for comparison. All other values were within normal ranges. (Supplemental Table 1 ).
Discussion
In this study, we show for the first time that porcine liver has rapid accumulation of the two FDA-approved hepatospecific MRI contrast agents, Eovist and Multihance, following IV injection of equivalent human doses. For Eovist, the pig data is very similar to that seen in humans, both in terms of time to peak signal enhancement (~10 minutes) and clearance rate from the liver to the bile (~50% in 1 hour) 18 . The porcine MRI enhancement following Multihance administration differs with humans, in that for humans, Multihance uptake by the liver is slow and inefficient, being mostly cleared by renal pathways. The pig results are similar to those previously observed in dogs, both for Eovist and Multihance, and are unsurprising given that both pigs and dogs express the same uptake transporter in hepatocytes, OATP1B4.
A major difference in scanning research animals versus companion animals is the type of information usually desired from the study. A clinical companion animal study employing hepatospecific MRI contrast agents likely seeks to identify tumors in the liver, or liver dysfunction. proper animal health must be maintained for the sake of the animal, there is a crucial need for proper animal health maintenance for reproducibility and accuracy of the data for research purposes. We observed that in this study, where for the two Eovist trials, despite being separated by five weeks and animal growth of 30 kg, keeping animal CBT within 1°F resulted in nearly identical temporal data of contrast agent uptake in the liver. This is contrasted with the two trials using Multihance, separated by only 1 week, where two very different temporal profiles were observed. We hypothesize that this was a result of overheating in Multihance 1 scan session -a 8.4°F CBT difference from Multihance 2 scan session. The temperature dependence of hepatospecific MRI contrast agent influx and efflux from the liver is well known in mice, with higher temperature resulting in faster uptake and clearance of agents from the liver 25 . This is apparently the case in swine as well.
There are some drawbacks to this study and lessons learned. First, only a single pig was imaged, albeit 5 different times. Thus, it is impossible to make generalizations about uptake kinetics of contrast agents in all pigs as there are different strains of pigs, just as there are different strains of mice and rats. Second, a comparison between uptake kinetics of each agent cannot be made as the dose of contrast agent used in this study was different. The human clinical doses of Eovist (0.025 mmol/kg) is ¼ that of Multihance (0.1 mmol/kg). A second study with equivalent dosing is required to make comparisons between contrast agent uptake kinetics. Third, we used an older VIBE sequence with Cartesian k-space sampling, resulting in somewhat noisy images and motion artifacts, particularly as the animal aged. Newer motion compensated abdominal imaging sequences with radial k-space sampling should mitigate these issues 26, 27 . Fourth, and perhaps not exactly a drawback, this study highlights a challenge in using domestic pigs for longitudinal studies. At purchase, the 2.5 month old pig weighed 25 kg and at the conclusion of the six-week study, the pig weighed 56.5 kg. This presents logistical challenges in performing serial imaging experiments on pigs past 5 or 6 months old that in some cases can be alleviated by using minipigs instead.
Conclusion
DCE-MRI of swine following IV injection of hepatospecific MRI contrast agents Eovist
and Multihance revealed rapid distribution of contrast agent in the blood, and high accumulation of contrast agent in the liver, shortly after injection. There was no retention of the non-specific agent Magnevist in the liver indicating it is not transported by hepatic OATPs, as expected. Proper animal health maintenance, especially temperature, seems essential for accurate and reproducible results. Given the disparity in contrast agent uptake kinetics with humans for Multihance, Eovist should be used in porcine models for biomedical imaging. Table S1 . Blood chemistry and other animal information for all scan sessions.
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